Drug intelligence / Profile preview

LYSG101

Development stage: Preclinical
Lead developer: Precisio Biotix Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intranasal

Overview

LYSG101 is an engineered lysin enzyme developed by Lysigen Biotechnology for the treatment of staphylococcal prosthetic joint infections (PJI). As a lysin, it functions as a highly specific antibacterial agent that targets and enzymatically degrades the peptidoglycan layer of the bacterial cell wall in Staphylococcus species, including Staphylococcus aureus. This mechanism leads to rapid osmotic lysis and death of the bacteria. LYSG101 is particularly aimed at addressing infections associated with biofilms on prosthetic implants, where traditional antibiotics often struggle to penetrate or remain effective.

Other names: LYSG101LYSG-101LYSG 101

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on LYSG101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYSG101.

Explore the full profile